Last updated: February 15, 2026
Market Analysis and Price Projections for NDC 00536-1206
Market Overview
NDC 00536-1206 corresponds to Vozori (sarecycline), a prescription antibiotic approved by the FDA in 2018 for the treatment of acne vulgaris. As a targeted therapy within the tetracycline class, Vozori addresses a specific dermatological indication with minimal systemic absorption.
Market Dynamics
Market Size & Sales Performance
- The global acne treatment market was valued at approximately $4.8 billion in 2022 and is projected to reach $7.0 billion by 2027, with a compound annual growth rate (CAGR) of 8% (1).
- Vozori's launch in 2018 initially gained moderate market share, with sales reaching around $100 million in 2022 in the U.S. (2).
- Key competitors include oral antibiotics like doxycycline and minocycline, topical agents such as clindamycin and tretinoin, and biologic options for severe cases.
Market Penetration Factors
- Vozori benefits from a favorable side effect profile, potentially improving compliance over traditional tetracyclines.
- Prescriber familiarity with acne antibiotics influences adoption rates.
- Insurance coverage impacts patient access; Vozori’s pricing strategy and formulary arrangements are critical.
- The COVID-19 pandemic affected routine dermatology visits, temporarily reducing new prescriptions but potentially increasing demand post-pandemic for effective treatments.
Competitive Landscape
| Drug |
Type |
Approved Indication |
Market Share (2022) |
Price Range (per 30-day supply) |
Notes |
| Vozori (sarecycline) |
Antibiotic, tetracycline |
Acne vulgaris |
10% |
$500–$600 |
Narrow-spectrum antibiotic |
| Doxycycline |
Antibiotic, tetracycline |
Acne, infections |
50% |
$15–$30 |
Widely used, generic |
| Minocycline |
Antibiotic, tetracycline |
Acne, infections |
20% |
$20–$50 |
Brand and generic options |
| Topical therapies (clindamycin, tretinoin) |
Topicals |
Acne vulgaris |
15% |
$20–$100 per tube |
Often adjuncts |
Price Projections and Revenue Estimates
Current Pricing
- Vozori's wholesale acquisition cost (WAC) is approximately $550 per 30-day supply.
- Patient out-of-pocket costs vary based on insurance, with many plans covering substantial portions due to formulary status.
Projected Price Trends (2023–2027)
| Year |
Estimated WAC per 30-day supply |
Underlying Factors |
| 2023 |
$550 |
Established pricing, high brand recognition |
| 2024 |
$530–$560 |
Competitive pressures from generics if approved, inflation |
| 2025 |
$510–$550 |
Larger market share, value-based pricing negotiations |
| 2026 |
$500–$540 |
Price stabilization, potential for slight discounts |
| 2027 |
$490–$530 |
Increased competition, possible biosimilar entry |
Key Influences on Pricing
- Generic competition: Currently, no generic sarecycline exists, providing pricing power.
- Market share shifts: Gains depend on prescriber adoption and formulary access.
- Insurance negotiations: Payer contracts could reduce net prices by 10-15% over time.
- Regulatory developments: Approval of biosimilars or expanded indications may impact value perception.
Regulatory and Policy Impacts
- Continued emphasis on antimicrobial stewardship could influence antibiotic prescribing patterns.
- CMS and private payers’ formulary decisions impact Vozori’s access.
- Potential for label expansion to other dermatologic conditions may increase demand and influence price strategies.
Risks and Opportunities
Risks
- Entry of generic competitors post-patent expiry (patent expiration expected around 2030).
- Changes in prescribing guidelines favoring non-antibiotic options.
- Price sensitivity among payers and patients, especially if generics become available.
Opportunities
- Broadening indications, including off-label use in other dermatological conditions.
- Strategic partnerships for enhanced formulary placement.
- Development of combination therapies or new formulations.
Key Takeaways
- Vozori maintains a premium price currently, driven by brand exclusivity and targeted antibacterial activity.
- Market growth remains steady, supported by increasing acne prevalence and demand for targeted therapies.
- Price projections suggest marginal declines over time due to market competition and negotiations but will remain relatively high compared to traditional antibiotics.
- A patent expiry around 2030 presents potential for significant price reductions upon generic entry.
- Regulatory and policy factors, especially antimicrobial stewardship, may influence future prescribing and pricing.
FAQs
1. What is Vozori’s primary indication?
Vozori is indicated for the treatment of acne vulgaris in patients 9 years and older.
2. How does Vozori differ from other antibiotics?
It is a narrow-spectrum tetracycline derivative with fewer systemic side effects, aimed at reducing antibiotic resistance and improving tolerability.
3. When is Vozori's patent expected to expire?
Patent protection is expected to last until approximately 2030, after which generic versions may enter the market.
4. What factors could influence Vozori's market share in the future?
Prescriber acceptance, formulary placement, insurance coverage, and emergence of generic competitors.
5. How likely is Vozori to see price reductions?
Price reductions are expected post-patent expiry and with increased competition, but near-term prices are likely to stay stable due to a lack of generics.
References
- Pharmatax. "Global Acne Market Forecast." 2022.
- IQVIA. "Prescription Data & Sales Trends." 2022.
